Peer-influenced content. Sources you trust. No registration required. This is HCN.
GoodRx for Healthcare Professionals
If approved, retatrutide will be the first in a new class of medications combining GIP, GLP-1, and glucagon receptor agonism in a single once-weekly injection.
Endocrinology, Diabetes, Metabolism March 13th 2026
Therapeutic Advances in Musculoskeletal Disease
Early treatment phases may transiently promote immune activation, whereas sustained therapy, by reducing BMI and lowering systemic inflammation, may mitigate this effect.
Cardiology March 13th 2026
MDLinx
“Hair loss can be very debilitating. We should start thinking about more proactive strategies to mitigate risks.” — Yagiz Matthew Akiska, MD/MPH candidate, George Washington University
Dermatology February 24th 2026
British Medical Journal (The BMJ)
Real world observations estimate that 50% of people with obesity discontinue GLP-1 receptor agonists within 12 months of initiation.
Cardiology February 6th 2026
Healthline
“People are more used to taking pills than they are taking injections” but “90% of a person’s weight is the result of what they eat. There are no magic solutions.”
Ambulatory Care Nursing January 29th 2026
Conexiant
The FDA concluded that GLP-1 RA medications are not associated with suicidal ideation or behavior and is requesting corresponding updates to product labeling.
Endocrinology, Diabetes, Metabolism January 27th 2026
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS